Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
MWN-AI** Summary
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing, has signed an agreement with renowned sports broadcaster Hannah Storm to promote awareness about the importance of knowing one’s family cancer history. Storm, a prominent figure who recently battled breast cancer herself, will serve as an ambassador for Myriad's Breast Cancer Risk Assessment Program, featuring the MyRisk® with RiskScore® Hereditary Cancer Test. This test is notable for being the first of its kind, integrating hereditary cancer risk evaluation for diverse ancestries.
In her advocacy role, Storm emphasizes that understanding personal and familial cancer risks is essential for effective prevention and treatment strategies. Given her experience as a mother of three daughters, Storm highlights that genetic insights can enable healthcare providers to recommend enhanced screening tools, which ultimately played a crucial role in the early detection of her own cancer. She encourages open family dialogues regarding health histories, noting that her late father's cancer diagnosis made her reevaluate her own risks, advocating for proactive health management.
Paul J. Diaz, President and CEO of Myriad Genetics, supports Storm's mission, noting that many women may lack awareness of their family health histories, which is vital for early cancer detection and prevention. Storm plans to leverage her social media platforms to further educate the public on hereditary cancer conversations and the necessity of understanding both maternal and paternal health backgrounds.
With Myriad's MyRisk® with RiskScore®, individuals can assess multiple genetic factors associated with various cancers, enabling personalized risk assessments. Myriad Genetics remains committed to advancing health through its innovative genetic testing solutions aimed at improving patient care and reducing healthcare costs.
MWN-AI** Analysis
Myriad Genetics, Inc. (NASDAQ: MYGN) recently announced a partnership with sports broadcaster Hannah Storm to raise awareness about the significance of understanding family cancer history. Given the increasing emphasis on preventive healthcare, this move positions Myriad Genetics favorably in a growing market for genetic testing, especially within oncology.
Storm’s personal narrative as a breast cancer survivor adds authenticity to the campaign, which promotes the MyRisk® with RiskScore® Hereditary Cancer Test. This industry-leading tool evaluates genetic markers to assess individual cancer risks. The collaboration highlights Myriad's commitment to educating both women and their healthcare providers about the importance of comprehensive risk assessment and early detection strategies.
From an investment perspective, this partnership could enhance Myriad’s brand visibility and credibility, particularly among women, which represents a considerable demographic in the healthcare market. The statement from Myriad’s CEO, Paul J. Diaz, underscores the potential of this initiative to inspire proactive health behaviors and discussions about family medical history, potentially driving demand for the company's testing solutions.
Moreover, as more women become aware of their hereditary cancer risks through awareness campaigns like this, it is likely to translate into higher adoption rates of genetic testing services. This is crucial as it may further solidify Myriad's leading position in the genetic testing market.
Investors should monitor the impact of this collaboration on user engagement and test uptake in the coming quarters. If effective, it may lead to revenue growth and improved market sentiment for Myriad Genetics. As healthcare becomes more personalized, the demand for innovative solutions like the MyRisk test is expected to rise, making MYGN a company to watch in the evolving landscape of genetic profiling and precision medicine.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm , a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer.
Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk ® with RiskScore ® Hereditary Cancer Test , the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. She will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks.
“Knowing your risk for breast cancer helps you and your provider come up with the game plan for prevention and treatment,” said Storm. “I’m a mother of three daughters, so another very important aspect of genetic testing for me is understanding what I could potentially be passing along to them. This information can help their clinicians determine if they would benefit from early detection tools like ultrasounds and MRIs. For me, additional screening made all the difference in catching my cancer at an early stage.”
“I didn't realize that it was really important to understand what kind of cancers were on both sides of your family. My father died of cancer, but it never occurred to me that because he had cancer that I might have an elevated risk of having cancer,” she continued.
Storm is a longtime SportsCenter anchor and NBC sports anchor, and host of the podcast “NBA DNA with Hannah Storm.” Her world changed in January 2024, when she was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS). A routine mammogram detected something suspicious, prompting an ultrasound, which led to a biopsy that revealed DCIS.
“We commend Hannah for raising awareness about the importance of knowing one’s family health history, as a survey suggests nearly half of women may not know their family health history 1 ,” said Paul J. Diaz, President and CEO, Myriad Genetics. “Working with someone of Hannah’s caliber and reach can encourage more women to engage in conversations about their family’s health history and consider potential preventive steps in consultation with their healthcare providers.”
Storm will share content about the importance of knowing family health history on her social media platforms. She plans to share a number of posts about how to have conversations with your family about hereditary cancers, the importance of knowing both sides of your family health history and what questions to ask.
About MyRisk ® Hereditary Cancer Test with RiskScore ®
MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com .
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that working with someone of Hannah’s caliber and reach can encourage more women to engage in conversations about their family’s health history and consider potential preventive steps in consultation with their healthcare providers. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
1 2022 Myriad Genetics Health Survey.
FAQ**
How could the partnership between Myriad Genetics and Hannah Storm potentially affect the market perception of Myriad Genetics in light of its agreement with Blackrock MuniYield Fund Inc. MYD?
What specific strategies will Myriad Genetics employ to measure the impact of Hannah Storm’s advocacy on public awareness compared to other investments like Blackrock MuniYield Fund Inc. MYD?
In what ways does the collaboration with Hannah Storm align with Myriad Genetics' long-term growth strategy, particularly in contrast to more traditional investment options such as Blackrock MuniYield Fund Inc. MYD?
How might changes in consumer engagement due to this partnership influence Myriad Genetics' financial performance relative to yields from investments in funds like Blackrock MuniYield Fund Inc. MYD?
**MWN-AI FAQ is based on asking OpenAI questions about Blackrock MuniYield Fund Inc. (NYSE: MYD).
NASDAQ: MYD
MYD Trading
0.56% G/L:
$10.79 Last:
38,526 Volume:
$10.73 Open:
